Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation Victoria Jacobs, NP, Heidi T. May, PhD, Tami L. Bair, RN, Brian G. Crandall, MD, Michael J. Cutler, DO, PhD, John D. Day, MD, Charles Mallender, MD, Jeffrey S. Osborn, MD, Scott M. Stevens, MD, J. Peter Weiss, MD, Scott C. Woller, MD, T. Jared Bunch, MD American Journal of Cardiology Volume 118, Issue 2, Pages 210-214 (July 2016) DOI: 10.1016/j.amjcard.2016.04.039 Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 1 Survival curve free of new stroke or TIA in patients with AF treated with DOACs versus warfarin. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 2 Survival curve free of major bleeds in patients with AF treated with DOACs versus warfarin. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 3 Survival curve free of total mortality in patients with AF treated with DOACs versus warfarin. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 4 Long-term incident dementia events in patients with AF compared by DOACs and warfarin treatment. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions
Figure 5 Survival curve for composite outcome of dementia, stroke, and TIA among DOAC and warfarin groups. American Journal of Cardiology 2016 118, 210-214DOI: (10.1016/j.amjcard.2016.04.039) Copyright © 2016 Elsevier Inc. Terms and Conditions